Loading
HRS-1167 is an experimental pill being studied to block a DNA-repair enzyme in cancer cells.
PARP1-selective inhibitor, licensed as M9466. The linked registry records distinguish recruiting, closed, and discontinued studies; those states do not establish comparative efficacy or approval. Merck KGaA reports discontinuing its M9466 development in its 2025 annual report. That sponsor decision does not mean the separate Hengrui studies have all stopped.
PARP1-selective inhibitor, licensed as M9466. Connects to PARP.
1.HRS-1167 slips into a pocket on PARP.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"HRS-1167" OR ABSTRACT:"HRS-1167" OR TITLE:"M9466" OR ABSTRACT:"M9466") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HRS-1167, not a curated reading list.
Shares PARP, Ovarian cancer, Breast cancer (all types).
Shares PARP, Ovarian cancer, Breast cancer (all types).
Shares PARP, Ovarian cancer, Breast cancer (all types).
Shares PARP, Ovarian cancer, Breast cancer (all types).
Shares PARP, Ovarian cancer, Breast cancer (all types).
Shares PARP, Ovarian cancer, Breast cancer (all types).
Shares PARP, Breast cancer (all types).
Shares PARP, Breast cancer (all types).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/